Market
Will AlphaFold AI-designed drug receive FDA approval for clinical trials by end of 2025?
2
Google DeepMind•Demis Hassabis•AlphaFold AI•Hassabis•Isomorphic Labs•World Economic Forum•Davos•Eli Lilly•Novartis
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements or official statements from Google DeepMind or Isomorphic Labs
Story
Google DeepMind's AlphaFold AI Drugs to Enter Clinical Trials by Year-End, Led by Nobel Prize Winner
Jan 24, 2025, 05:54 PM
Google DeepMind's CEO, Demis Hassabis, has announced that the company's AI-designed drugs, developed using the AlphaFold AI technology, are expected to enter clinical trials by the end of the year. These drugs target major therapeutic areas including cancer, heart disease, and neurodegenerative diseases. Hassabis, a Nobel Prize winner and leader of Isomorphic Labs, a Google DeepMind spinoff, stated that the AI technology aims to reduce the drug discovery process from a decade to weeks or months. The announcement was made during a panel at the World Economic Forum in Davos. Isomorphic Labs has already established strategic research collaborations with pharmaceutical giants Eli Lilly and Novartis to further this initiative.
View original story
Similar markets
Cancer treatment • 25%
Autoimmune diseases • 25%
Viral infections • 25%
Bacterial infections • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Conditional Approval • 25%
Full Approval • 25%
Accelerated Approval • 25%
Rejection • 25%
Breakthrough Prize • 25%
Nobel Prize • 25%
No major award • 25%
Lasker Award • 25%
Licensing Agreement • 25%
No further development • 25%
Partnership with NGO • 25%
Phase 1 Clinical Trials • 25%